Publications

Peer-Reviewed Journal Articles:

  1. Zafari Z, Sadatsafavi M,  Fitzgerald M, Canadian Resp Research Network, “Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US”, BMC Cost Eff Resource Alloc, 2018
  2. Zafari Z, Sadatsafavi M, Chen W, Fitzgerald M, “The projected economic and health burden of sub-optimal asthma control in Canada”, Respiratory Medicine, 2018.
  3. Zafari Z, Jiao B, Brian W, Li S, Muennig PA, “The Trade-Off between Optimizing Flight Patterns and Human Health: A Case Study of Aircraft Noise
    in Queens, NY, USA”, Accepted in Int. J. of Env. Research and Public Health, 2018.
  4. Zafari Z, Lynd LD, FitzGerald JM, Sadatsafavi M, “Economic and health effect of full adherence to controller therapy in adults with uncontrolled asthma: a simulation study”, J Allergy Clin Immunol (JACI), 2014.
  5. Zafari Z, Don D. Sin, Dirkje S. Postma, Claes-Göran Löfdahl, Judith Vonk, Stirling Bryan, Stephen Lam, C. Martin Tammemagi, Rahman Khakban, S.F. Paul Man, Donald Tashkin, Robert A. Wise, John E. Connett, Bruce McManus, Raymond Ng, Zsuszanna Hollander, Mohsen Sadatsafavi, “Individualized prediction of lung function decline in COPD”, Canadian Medical Association Journal (CMAJ), 2016.
  6. Zafari Z, Thorlund K, FitzGerald JM, Marra CA, Sadatsafavi M, “Network vs. pairwise meta-analyses: a case study of the impact of an evidence-synthesis paradigm on value of information outcomes”, Pharmacoeconomics, 2014.
  7. Zafari Z, Sadatsafavi M, Marra CA, Chen W, Fitzgerald JM, “Cost-effectiveness of bronchial thermoplasty, omalizumab, and standard therapy for moderate-to-severe allergic asthma”, PLOS ONE 2016.
  8. Zafari Z, Bryan S, Sin D, Conte T, Khakban R, Sadatsafavi M, “A systematic review of health economics simulation models of chronic obstructive pulmonary disease”, Value in Health, 2016.
  9. Sadatsafavi M, Bansback N, Zafari Z, Najafzadeh M, Marra C, “Need for speed: an efficient algorithm for calculation of single-parameter expected value of partial perfect information”, Value Health, 2013.
  10. Levin D, Bell S, Sund R, Hartikainen SA, Tuomilehto J, Pukkala E, Keskimäki I, Badrick E, Renehan AG, Buchan IE, Bowker SL, Minhas-Sandhu JK, Zafari Z, Marra C, Johnson JA, Stricker BH, Uitterlinden AG, Hofman A, Ruiter R, de Keyser CE, MacDonald TM, Wild SH, McKeigue PM, Colhoun HM; Scottish Diabetes Research Network Epidemiology Group; Diabetes and Cancer Research Consortium, “Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis”, Diabetologia, 2015.
  11. Khakban A, Sin DD, FitzGerald JM, Ng R, Zafari Z, McManus B, Hollander Z, Marra CA, Sadatsafavi M, “10-Year Trends in Direct Costs of COPD: A Population Based Study”, Chest 2015.
  12. Sadatsafavi M, Lynd LD, De Vera MA, Zafari Z, FitzGerald JM, “One-year outcomes of inhaled controller therapies added to systemic corticosteroids after asthma-related hospital discharge”, Respir Med, 2015.
  13. Thorlund K, Zafari Z, Druyts E, Mills EJ, Sadatsafavi M, “The impact of incorporating Bayesian network meta-analysis in cost-effectiveness analysis-a case study of pharmacotherapies for moderate to severe COPD”, Cost Eff Resour Alloc, 2014.
  14. Abdulrahman Alshabanat A, Zafari Z, Dairi M, Albanyan O, Fitzgerald JM, “Asthma and COPD Overlap Syndrome (ACOS): A Systematic Review and Meta-analysis”, PLOS ONE, 2015.
  15. Chen W, Marra C, Lynd, L, Fitzgerald JM, Zafari, Z, Sadatsafavi M, “The natural history of severe asthma and influences of early risk factors: a population-based cohort study”, Thorax, 2016.
  16. Sadatsafavi M, Sin D, Zafari Z, Criner G, Connett J E, Woodruff P, Lazarus S, Han M, Martinez F, Albert R, “The association between exacerbation rate and severity in chronic obstructive pulmonary disease: an application of a joint frailty-logistic model”, American Journal of Epidemiology (AJE), 2016.
  17. Tsao N, Khakban A, Gastonguay L, Zafari Z, Lynd L, Marra C, “Opinions and preferences of British Columbia pharmacists and physicians on medication management services”, Canadian Pharmacists Journal, 2016.
  18. Khakban A, Mohammadi T, Lynd L, Mabbott D, Bouffet E, Gastonguay L, Zafari Z, Malkin D, Taylor M, Marra C, “Societal Preferences in the Treatment of Pediatric Medulloblastoma: Balancing Risk of Death and Quality of Life”, Pediatric Blood & Cancer, 2016.
  19. Nikoo M, Vogel M, Choi F, Song MJ, Burghardt J, Zafari Z, Tabi K, Frank A, Barbic S, Schütz C, Jang K, Krausz M, “Employment and paid work among participants in a randomized controlled trial comparing diacetylmorphine and hydromorphone”, Int. Journal of Drug Policy, 2018.
  20. Sadatsafavi M, Gustafson P, Zafari Z, Sin D, “Relative Impact Characteristic (RIC) curve: a graphical tool to visualize and quantify the clinical utility and population-level consequences of implementing markers”, Annals of Epidemiology, 2018.
  21. Zafari Z, Tavakoli J, “New Approach for Fuzzy Control and Analysis of Queueing System with Flexible Service Time”, IMECS 2011, ISBN: 978-988-19251-2-1.
  22. Kim S, Zafari Z, Bellanger M, Muennig PA, “The cost-effectiveness of capping freeways for use as parks in the name of population health: the Cross-Bronx Expressway case study”, American Journal of Public Health (AJPH), 2018.
  23. Li S, Jiao B, Zafari Z, Muennig PA, “Optimising the cost-effectiveness of speed limit enforcement cameras”, Injury Prevention, 2018.
  24. Guo MY, Etminan M, Cheng JZ, Zafari Z, Maberley D, “One-Year Effectiveness Study of Intravitreous Ranibizumab in Wet (Neovascular) Age-Related Macular Degeneration: A Meta-Analysis”, Pharmacotherapy, 2018.
  25. Jiao B, Zafari Z, Will B, Ruggeri K, Li S, Muennig PA, “The Cost-Effectiveness of Lowering Permissible Noise Levels Around U.S. Airports”, Int. Journal of Environ. Res and Public Health, 2017.
  26. Guo MY, Cheng J, Etminan M, Zafari Z, Maberley D, “One year effectiveness study of intravitreal aflibercept in neovascular age-related macular degeneration: a meta-analysis”, Acta Ophthalmologica, 2018.
  27. Muennig P, Reynolds M, Fink D, Zafari Z, Geronimus A, “America’s declining well-being, health, and life expectancy: not just a white problem”, Accepted in AJPH, 2018.
  28. Khakban A, Mohammadi T, Lynd L, Mabbott D, Bouffet E, Gastonguay L, Zafari Z, Malkin D, Taylor M, Marra C, “How do parents and providers trade off between disability and survival? Preferences in the treatment of pediatric medulloblastoma”, Accepted in Patient Preference and Adherence, 2018.
  29. Ruggeri K, Ivanović N, Razum J, Kácha O, Menezes IG, Zafari Z, Garcia-Garzon E, “An advance-based policy for managing global health access through medical travel”, Minor revisions in Health Policy, 2018.
  30. Yu W, Chen C, Jiao B, Zafari Z, Muennig P, “The Cost-Effectiveness of Bike Share Expansion to Low-Income Communities in New York City”, Minor revisions in Journal of Urban Health, 2018.
  31. Zafari Z, Muennig PA, “Health and Economic Benefits of Housing Vouchers that Relocate Residents of Low-Income Neighborhoods”, under review.
  32. Sooyoung K, Platt I, Xiao C, Zafari Z, Muennig P, Bellanger M, “Health and economic consequences of introducing stricter US PM2.5 vehicle emissions standards to the EU”, under review.
  33. Jiao B, Zafari Z, Ruggeri K, Williams S, “Sexually transmitted disease and depression: evidence from a predominantly Hispanic neighborhood of New York City”, under review.
  34. Lv Y, Zafari Z, Jiao B, Chun C, Zhang L, Muennig P, “The cost effectiveness of mandates for government control of autonomous vehicles in earthquake emergency rescue”, under review.

Published Full Reports:

  1. Zafari Z, Bryan S, Mitton C, Sadatsafavi M, “Evaluating the Cancer Risk Management Model (CRMM)-Colorectal Cancer Module”, Accessible from Canadian Task Force.
  2. Sadatsafavi M, Zafari Z, Mitton C, Bryan S, “Evaluating the Cancer Risk Management Model (CRMM)-Lung Cancer Module”, Accessible from Canadian Task Force.

Published Abstracts:

  1. Zafari Z, Sadatsafavi M, Chen W, Fitzgerald M. “The long-term projection of health ad economic burden of sub-optimal asthma control in Canada”, American J. of Resp. and Critical Care Medicine, 2018; 197:A1091.
  2. Zafari Z, S. Bryan, D. Sin, C. A. Marra, M. Sadatsafavi, “Value of characterizing heterogeneity in chronic obstructive pulmonary disease”, CADTH 2016, Ottawa, Canada.
  3. Zafari Z, D. Sin, S. Bryan, M. Sadatsafavi, “The ideal biomarker to predict COPD exacerbations”, Am J Respir Crit Med 193;2016:A3508.
  4. Zafari Z, M. Fitzgerald, C. Marra, M. Sadatsafavi, “Cost-effectiveness of tiotropium versus omalizumab for patients with severe uncontrolled asthma in US”, Am J Respir Crit Med 191;2015:A3712.
  5. Zafari Z, D. D. Sin, S. Bryan, A. Khaban, B. M. McManus, R. Ng, Z. Hollander, M. Sadatsafavi, “Characterizing heterogeneity in lung function decline in COPD”, Am J Respir Crit Med 191;2015:A2434.
  6. Zafari Z, D. Sin, S. Bryan, M. Sadatsafavi, “Informing micro-simulation economic models from patient-level data using mixed-model regression: theory and implications”, iHEA 2015, 11th World Congress, Milan Italy.
  7. A. Khakban, D. Sin, R. Ng, Zafari Z, M. FitzGerald, B. McManus, Z. Hollander, C. Marra, Mohsen Sadatsafavi, “The Economic Burden of COPD in British Columbia from 2001 to 2010: A Population Based Study”, iHEA 2015, 11th Word Congress, Milan, Italy.
  8. Zafari Z, M. Sadatsafavi, M. Fitzgerald, L. Lynd, C. Marra, “The Humanistic and Economic Impact of Following Evidence-Based Asthma Controller Therapy: A Simulation Study”, Value in Health, Volume 16, Issue 3 , Page A235, May 2013.
  9. Zafari Z, K. Thorlund, M. Fitzgerald, L. Lynd, C. Marra, M. Sadatsafavi, “Impact of multiple treatment comparison meta-analysis on value of information evaluations: a case study of pharmacotherapies for chronic obstructive pulmonary diseases”, Value in Health, Volume 16, Issue 3 , Pages A26-A27, May 2013.
  10. G. Moullec, R. Rousseau, W. Chen, M. Sadatsafavi, Zafari Z, A. Bekirov, M. J. FitzGerald, EBA study group, “Combined Effect of Psychological Distress and Asthma Control on Productivity Loss in Patients with Asthma: A Population-Based Study”, Am J Respir Crit Care Med, 189;2014:A2301.
  11. J. M. FitzGerald, W. Chen, C. A. Marra, L. Lynd, R. Rousseau, Zafari Z, E. McClymont, M. Sadatsafavi, EBA Study Group, “The Influence of Asthma Impairment and Comorbidities on Health-Related Quality of Life”, Am J Respir Crit Care Med 189;2014:A1379.
  12. Amir Khakban, Louise Gastonguay, Larry Lynd, Tima Mohammadi, Zafari Z, Michael Taylor, Eric Bouffet, David Malkin, Carlo Marra, “Using best-worst scaling to evaluate trade-offs between quality of life and survival in pediatric medulloblastoma treatment”, Oral presentation in iHEA 2014, 10th world congress, Dublin, July 13-16, 2014.
  13. Anik R. Patel, Carlo A. Marra,  R. Scott Braithwaite , Zafari Z, Mia L. van der Kop, Richard T. Lester, “Cost-effectiveness of the WelTel mHealth program to improve adherence rates to antiretroviral therapy in Kenya”, Poster presentation in 6th Annual BCCDC Research Symposium, Vancouver, November 18-22, 2013.
  14. Zafari Z, Y. Zhao, J. Tavakoli, “The exact tail asymptotic of a general random walk model in the first and fourth quadrants”, Canadian Operational Research Society (CORS), Niagara Falls, June 11-13, 2012.
  15. Z. Zafari, Y. Zhao, J. Tavakoli, “Analysis of exact tail asymptotic behaviour of the joint stationary distribution of the continuous-time JSQ (Joint the Shortest Queue)”, CanQueue 2011, Banff, Aug 26-28, 2011.
  16. Zafari Z, J. Tavakoli “Healthcare Queueing System Fuzzy Control Approach for Reducing Sojourn Time”, INFORMS, Montreal, June 20-22, 2011.
  17. Zafari Z, “The Exact Tail Asymptotic Behaviour of the Joint Stationary Distributions of the Generalized Join the Shortest Queueing Model”, Master of Science Thesis 2012, University of British Columbia, Canada.